Company Overview and News
Shares of Canadian Pacific Railway Limited (CP - Free Report) hit a 52-week high of $194.74 during the trading session on Jun 11, before retracing a bit to close at $193.79. Notably, the stock has performed impressively in a year with a 23.8% gain, outperforming the industry’s rally of 20.4%.
GATX EXPD CP CP SKYW GMTA GMT
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Dividend growth investing is a popular model followed by the investing community to build assets. Companies which not only pay dividends, but raise them year after year have been shown to perform better overall for investor returns.
LRCX CP PAG PSX KGI.DB QBCRF BMO 1128 CP AAPL CAH KL LEG WYNN KGI KGI.DB.A OTEX BMO WYNMF OTC NTAP TU QBCAF WYNMY
MONTREAL/VANCOUVER (Reuters) - In a battle to unclog rail bottlenecks that left Canadian commodities trapped in landlocked western provinces this winter, the country’s largest railways are offering C$15,000 ($11,566.93) signing bonuses for experienced workers who can hit the rails right away and get trains moving.
June 7 (Reuters) - Stock futures for Canada’s main stock index were little changed on Thursday as gains in oil prices on concerns of a drop in Venezuelan exports were kept in check by surging production from the United States.
MONTREAL, June 6 (Reuters) - Canadian Pacific Railway Ltd conductors and locomotive engineers will get a 9 percent salary hike over four years as part of a tentative agreement reached last week with the Teamsters, a union spokesman said on Wednesday.
MONTREAL (Reuters) - Canadian Pacific Railway Ltd conductors and locomotive engineers will get a 9 percent salary hike over four years as part of a tentative agreement reached last week with the Teamsters, a union spokesman said on Wednesday.
Canadian National Railway Company (CNI - Free Report) announced ratification of its new contract with Brotherhood of Locomotive Engineers and Trainmen (BLET), representing 475 locomotive engineers on its Illinois Central (IC) property in the United States. The contract runs through Dec 31, 2019 and offers better wages and other benefits commensurate with industry standards every year under the agreement.
GATX EXPD CP CP GMTA GMT
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to CP / Canadian Pacific Railway Ltd. on message board site Silicon Investor.
as of ET